ATE283285T1 - Globularer aufbau vom amyloid-beta- protein und deren verwendungen - Google Patents

Globularer aufbau vom amyloid-beta- protein und deren verwendungen

Info

Publication number
ATE283285T1
ATE283285T1 AT00952571T AT00952571T ATE283285T1 AT E283285 T1 ATE283285 T1 AT E283285T1 AT 00952571 T AT00952571 T AT 00952571T AT 00952571 T AT00952571 T AT 00952571T AT E283285 T1 ATE283285 T1 AT E283285T1
Authority
AT
Austria
Prior art keywords
addls
activity
formation
amyloid beta
compounds
Prior art date
Application number
AT00952571T
Other languages
English (en)
Inventor
Grant A Krafft
William L Klein
Brett A Chromy
Mary P Lambert
Caleb E Finch
Todd Morgan
Pat Wals
Irina Rozovsky
Ann Barlow
Original Assignee
Univ Southern California
Univ Northwestern
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23454671&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE283285(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Southern California, Univ Northwestern filed Critical Univ Southern California
Application granted granted Critical
Publication of ATE283285T1 publication Critical patent/ATE283285T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT00952571T 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen ATE283285T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US36923699A 1999-08-04 1999-08-04
PCT/US2000/021458 WO2001010900A2 (en) 1999-08-04 2000-08-04 Globular assembly of amyloid beta protein and uses thereof

Publications (1)

Publication Number Publication Date
ATE283285T1 true ATE283285T1 (de) 2004-12-15

Family

ID=23454671

Family Applications (2)

Application Number Title Priority Date Filing Date
AT00952571T ATE283285T1 (de) 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen
AT04027742T ATE445639T1 (de) 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT04027742T ATE445639T1 (de) 1999-08-04 2000-08-04 Globularer aufbau vom amyloid-beta- protein und deren verwendungen

Country Status (9)

Country Link
EP (2) EP1571158B1 (de)
JP (1) JP4796725B2 (de)
AT (2) ATE283285T1 (de)
AU (1) AU6524500A (de)
CA (1) CA2381323C (de)
DE (2) DE60016227T2 (de)
ES (1) ES2235926T3 (de)
HK (1) HK1047944A1 (de)
WO (1) WO2001010900A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030068316A1 (en) * 1997-02-05 2003-04-10 Klein William L. Anti-ADDL antibodies and uses thereof
US7179892B2 (en) 2000-12-06 2007-02-20 Neuralab Limited Humanized antibodies that recognize beta amyloid peptide
US7790856B2 (en) 1998-04-07 2010-09-07 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize beta amyloid peptide
US7588766B1 (en) 2000-05-26 2009-09-15 Elan Pharma International Limited Treatment of amyloidogenic disease
US6913745B1 (en) 1997-12-02 2005-07-05 Neuralab Limited Passive immunization of Alzheimer's disease
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US6761888B1 (en) 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
US6905686B1 (en) 1997-12-02 2005-06-14 Neuralab Limited Active immunization for treatment of alzheimer's disease
US7964192B1 (en) 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
EA006606B1 (ru) 2000-02-24 2006-02-24 Вашингтон Юниверсити Гуманизированное антитело и его фрагмент, взаимодействующие с бета-амилоидным пептидом, и способы их применения
AU2001268005A1 (en) 2000-07-07 2002-01-21 Lars Lannfelt Prevention and treatment of alzheimer's disease
PE20020574A1 (es) 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
US7700751B2 (en) 2000-12-06 2010-04-20 Janssen Alzheimer Immunotherapy Humanized antibodies that recognize β-amyloid peptide
EP1944040B1 (de) 2001-08-17 2012-08-01 Washington University Assay-Verfahren für Alzheimer
EP1288226A1 (de) * 2001-09-03 2003-03-05 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Modifizierung der Geneexpression der Mitglieder von "Toll"-ähnlicher Rezeptorfamilie zur Beeinflussung der Neurodegeneration und der Neuroprotektion im menschlichen Zentralnervensystem
MY139983A (en) 2002-03-12 2009-11-30 Janssen Alzheimer Immunotherap Humanized antibodies that recognize beta amyloid peptide
EP1535056A1 (de) * 2002-07-31 2005-06-01 Solvias AG Vorrichtung und messverfahren
JP2006508072A (ja) * 2002-10-01 2006-03-09 ノースウエスタン ユニバーシティ アミロイドベータ由来拡散性リガンド（ＡＤＤＬｓ）、ＡＤＤＬ代替物、ＡＤＤＬ結合性分子、およびそれらの使用
DE10303974A1 (de) * 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
ES2344645T3 (es) 2003-02-10 2010-09-02 Applied Molecular Evolution, Inc. Moleculas de union al abeta.
TWI306458B (en) 2003-05-30 2009-02-21 Elan Pharma Int Ltd Humanized antibodies that recognize beta amyloid peptide
US8250823B2 (en) 2003-08-26 2012-08-28 Ejot Gmbh & Co. Kg Dowels and methods for the assembly of insulating panels
JP2008500286A (ja) * 2004-05-14 2008-01-10 ノースウエスタン ユニバーシティ Ａｄｄｌ受容体を含む組成物、関連する組成物、および関連する方法
SE0401601D0 (sv) 2004-06-21 2004-06-21 Bioarctic Neuroscience Ab Protofibril specific antibodies and uses thereof
ES2396555T3 (es) 2004-12-15 2013-02-22 Janssen Alzheimer Immunotherapy Anticuerpos que reconocen péptido beta amiloide
EP1838348B1 (de) 2004-12-15 2013-06-26 Janssen Alzheimer Immunotherapy Humanisierte amyloid-beta-antikörper zur verbesserung der kognition
KR20080021585A (ko) 2005-03-05 2008-03-07 애보트 게엠베하 운트 콤파니 카게 스크리닝 방법, 비확산성 ａ-베타 올리고머의 정제 방법,당해 비확산성 ａ-베타 올리고머에 대한 선택적 항체 및당해 항체의 제조 방법
DE102005014936A1 (de) 2005-03-24 2006-12-14 Abbott Gmbh & Co. Kg Substituierte Oxindol-Derivate, diese enthaltende Arzneimittel und deren Verwendung
TW200726774A (en) * 2005-06-30 2007-07-16 Merck & Co Inc Composition and method for producing stable amyloid beta oligomers
RU2442793C2 (ru) 2005-11-30 2012-02-20 Эбботт Лэборетриз АНТИТЕЛА ПРОТИВ ГЛОБУЛОМЕРА Аβ, ИХ АНТИГЕНСВЯЗЫВАЮЩИЕ ЧАСТИ, СООТВЕТСТВУЮЩИЕ ГИБРИДОМЫ, НУКЛЕИНОВЫЕ КИСЛОТЫ, ВЕКТОРЫ, КЛЕТКИ-ХОЗЯЕВА, СПОСОБЫ ПОЛУЧЕНИЯ УКАЗАННЫХ АНТИТЕЛ, КОМПОЗИЦИИ, СОДЕРЖАЩИЕ УКАЗАННЫЕ АНТИТЕЛА, ПРИМЕНЕНИЯ УКАЗАННЫХ АНТИТЕЛ И СПОСОБЫ ИСПОЛЬЗОВАНИЯ УКАЗАННЫХ АНТИТЕЛ
JP2009518010A (ja) 2005-11-30 2009-05-07 アボット・ラボラトリーズ ヒトβアミロイドタンパク質の組み換え形態の調製方法及びこれらのタンパク質の使用
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
MY169492A (en) 2006-03-23 2019-04-15 Bioarctic Neuroscience Ab Improved protofibril selective antibodies and the use thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
WO2008088983A1 (en) 2007-01-18 2008-07-24 Eli Lilly And Company PEGYLATED Aβ FAB
US8895004B2 (en) 2007-02-27 2014-11-25 AbbVie Deutschland GmbH & Co. KG Method for the treatment of amyloidoses
US8003097B2 (en) 2007-04-18 2011-08-23 Janssen Alzheimer Immunotherapy Treatment of cerebral amyloid angiopathy
ES2498040T3 (es) 2007-07-27 2014-09-24 Janssen Alzheimer Immunotherapy Tratamiento de enfermedades amiloidogénicas con anticuerpos anti-beta humanizados
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
US9217024B2 (en) 2007-12-18 2015-12-22 Acumen Pharmaceuticals, Inc. ADDL receptor polypeptides, polynucleotides and host cells for recombinant production
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
SI2448968T1 (sl) * 2009-06-29 2021-07-30 Bioarctic Ab Protitelesa, selektivna za protofibrile/oligomere na N-koncu skrajšanega amiloida-beta
EP2368558A1 (de) 2010-03-23 2011-09-28 Mdc Max-Delbrück-Centrum Für Molekulare Medizin Berlin - Buch Azoverbindungen zur Reduzierung der Bildung und der Toxizität von Amyloid-Beta-Aggregationszwischenprodukten
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
US9062101B2 (en) 2010-08-14 2015-06-23 AbbVie Deutschland GmbH & Co. KG Amyloid-beta binding proteins
CN103782171B (zh) 2011-07-13 2016-12-14 默沙东公司 用于检测流体样品中淀粉状蛋白β寡聚体的方法及其用途
WO2013164763A2 (en) 2012-04-30 2013-11-07 Innovative Health Diagnostics A biological complex specific for alzheimer's disease detection in vitro and use thereof
CN106661103B (zh) 2014-07-10 2020-11-03 生命北极神经科学公司 改进的Aβ初原纤维结合抗体
US20190015361A1 (en) * 2017-07-17 2019-01-17 Maxwell Biosciences, Inc. Polytherapy modulating cathelicidin gene exprtession modulation for the treatment of alzheimer's disease and other conditions
US12685490B2 (en) 2020-01-28 2026-07-21 The Board Of Trustees Of The Leland Stanford Junior University Method of preventing or treating pancreatic dysfunction or diabetes by upregulating human cathelicidin LL-37 to inhibit islet amyloid polypeptide (IAPP) self-assembly
WO2023107830A1 (en) * 2021-12-06 2023-06-15 The Board Of Trustees Of The Leland Stanford Junior University Amyloid oligomer compositions

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5948763A (en) 1995-06-07 1999-09-07 New York University Peptides and pharmaceutical compositions thereof for treatment of disorders or diseases associated with abnormal protein folding into amyloid or amyloid-like deposits
US6218506B1 (en) * 1997-02-05 2001-04-17 Northwestern University Amyloid β protein (globular assembly and uses thereof)
EP1007048A4 (de) * 1997-03-11 2004-09-22 Gen Hospital Corp Identifizierung von mitteln zur behandlung der alzheimerischen krankheit

Also Published As

Publication number Publication date
HK1047944A1 (zh) 2003-03-14
EP1571158B1 (de) 2009-10-14
DE60043165D1 (de) 2009-11-26
EP1200470B1 (de) 2004-11-24
WO2001010900A2 (en) 2001-02-15
AU6524500A (en) 2001-03-05
EP1571158A3 (de) 2007-03-14
DE60016227T2 (de) 2005-12-15
DE60016227D1 (de) 2004-12-30
ATE445639T1 (de) 2009-10-15
ES2235926T3 (es) 2005-07-16
EP1571158A2 (de) 2005-09-07
EP1200470A2 (de) 2002-05-02
WO2001010900A3 (en) 2001-08-30
JP2003510023A (ja) 2003-03-18
CA2381323C (en) 2009-10-06
JP4796725B2 (ja) 2011-10-19
CA2381323A1 (en) 2001-02-15

Similar Documents

Publication Publication Date Title
ATE445639T1 (de) Globularer aufbau vom amyloid-beta- protein und deren verwendungen
ATE349467T1 (de) Amyloid beta protein (globularer aufbau und seine verwendung)
ATE485303T1 (de) Isoformen von gehirn-natriuretischem peptid
ATE466883T1 (de) Katalytische monoklonale antikörper mit proteaseaktivität zur selektiven lysis der proteinkomponente von mit pathologischen konditionen zusammenhängenden plaques und aggregaten
BR0315688A (pt) Compostos, composições farmacêuticas e seus usos no tratamento ou prevenção de doenças ou condições de proliferação celular metabólicas
EP1218368A4 (de) Zusammensetungen und verfahren zur modulation von apoptose in cellen, die proteine der bc1-2-familie exprimieren
WO1999015658A3 (en) Human regulatory molecules
DE60233955D1 (de) Spezifische bindungsmittel von human angiopoietin-2
FI963101L (fi) Anti-TNF-vasta-aineiden käyttö lääkkeenä sellaisten sairauksien hoitoon, joissa seerumin interleukiini-6-taso on kohonnut
KR890700666A (ko) 혈관 항응고 단백질, 이를 암호화하는 dna, 이의 제조방법 및 용도
NO993424D0 (no) Fremgangsmåte til selektiv nedbrytning av melkeprotein i naervaer av andre melkeproteiner
ATE425183T1 (de) P53-bindendes polypeptid
WO2000013015A8 (en) Modulating multiple lineage kinase proteins
ATE221663T1 (de) Prionbindende proteine und deren verwendungen
WO2000052151A3 (en) Human secretory proteins
WO1999033870A3 (en) Human regulatory proteins
WO2001044448A3 (en) Human oxidoreductase proteins
WO2004017992A3 (en) Ptk7 protein involvement in carcinoma
BR9811907A (pt) Proteìna de ligação de lactoferrina de neisseria
WO2002062205A3 (en) Methods for diagnosing and treating heart disease
IS6098A (is) Ósantant til meðhöndlunar á skaptruflunum
WO2002014536A3 (en) Odulating multiple lineage kinase proteins
WO2003028536A3 (en) Methods for diagnosing and treating heart disease
WO2004013629A3 (en) Screening for agents suitable for treatment of leukocyte associated inflammatory diseases
NO920524D0 (no) Kynurensyrederivater, deres fremstilling og farmasoeytiskeblandinger inneholdende disse

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties